|
|
Volumn 2013, Issue , 2013, Pages
|
|
Osteosarcoma: Lessons learned and future avenues
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE ANTIBODY;
ANTIBODY CONJUGATE;
ANTINEOPLASTIC AGENT;
BETA CATENIN;
BIOLOGICAL MARKER;
DICKKOPF 3 PROTEIN;
DOXORUBICIN;
GLYCOPROTEIN;
MONOCLONAL ANTIBODY;
NANOPARTICLE;
PEGINTERFERON;
RIDAFOROLIMUS;
UNCLASSIFIED DRUG;
WNT PROTEIN;
BONE METASTASIS;
CANCER CELL CULTURE;
CANCER COMBINATION CHEMOTHERAPY;
CANCER PROGNOSIS;
CANCER SURVIVAL;
CHILDHOOD CANCER;
DOWN REGULATION;
DRUG EFFICACY;
EDITORIAL;
ENZYME INHIBITION;
EVENT FREE SURVIVAL;
EWING SARCOMA;
GENETIC TRANSFECTION;
GERM CELL TUMOR;
HUMAN;
LIPOSOMAL GENE DELIVERY SYSTEM;
LONG TERM SURVIVAL;
MESENCHYMAL STEM CELL;
MOLECULARLY TARGETED THERAPY;
MULTICENTER STUDY (TOPIC);
ONCOGENE H RAS;
OSTEOSARCOMA;
OSTEOSARCOMA CELL;
PATIENT COMPLIANCE;
PHASE 2 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RHABDOMYOSARCOMA;
SIGNAL TRANSDUCTION;
SYSTEMIC THERAPY;
TREATMENT REFUSAL;
TREATMENT RESPONSE;
TUMOR XENOGRAFT;
|
|
EID: 84884833685
PISSN: 1357714X
EISSN: 13691643
Source Type: Journal
DOI: 10.1155/2013/641687 Document Type: Editorial |
|
Times cited : (4)
|
|
References (4)
|
